Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4 percent of their body weight after 72 ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...

Live Updates Live Coverage Updates appear automatically as they are published. Discovery-ing Some Profits 9:40 am Continuing ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...